Navigation Links
GenVec Reports Inducement Award
Date:5/25/2012

GAITHERSBURG, Md., May 25, 2012 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC) announced today that on May 23, 2012 it granted an option to purchase shares of its common stock to Cynthia Collins, its newly appointed President and Chief Executive Officer.  The option grant was approved by the Compensation Committee of GenVec's Board of Directors and the Board of Directors, and was made as an inducement material to Ms. Collins's acceptance of employment with GenVec in accordance with NASDAQ Listing Rule 5635(c)(4).

The option allows for the purchase of up to 250,000 shares of GenVec's common stock at an exercise price per share equal to $2.54, the closing price of the Company's common stock on May 23, 2012.  The option has a ten-year term and will vest and become exercisable as to one-eighth (1/8th) of the shares of common stock covered by the option on the six month anniversary of the grant date and, on the first day of each month thereafter, the option will vest and become exercisable as to an additional one-forty-eighth (1/48th) of the shares of common stock covered by the option until the option is fully exercisable.

On May 24, 2012, GenVec filed a Form 8-K regarding the appointment of Ms. Collins and related matters.  Please refer to that filing for a full description of the inducement award agreement pursuant to which the option was granted.  GenVec is providing this information in accordance with NASDAQ Listing Rule 5635(c)(4).

About GenVec
GenVec is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, malaria, and human immunodeficiency virus (HIV). In the area of animal health, we are developing vaccines against foot-and-mouth disease (FMD). Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.

Retail Investor and Media Contact:     

GenVec, Inc.

Douglas J. Swirsky

(240) 632-5510

dswirsky@genvec.com

Institutional Investor Contact:

S.A. Noonan Communications

Susan A. Noonan

(212) 966-3650

susan@sanoonan.com


'/>"/>
SOURCE GenVec, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GenVec Appoints Cynthia Collins as President and CEO
2. GenVec To Release First Quarter 2012 Financial Results And Conduct A Conference Call On May 10, 2012
3. GenVec to Release Fourth Quarter and Year-End 2011 Financial Results and Conduct a Conference Call on March 15, 2012
4. Faruqi & Faruqi, LLP Announces Investigation of GenVec, Inc.
5. GenVec Extends Research Collaboration with Global Pharmaceutical Company
6. GenVec Reports Third Quarter 2011 Financial Results
7. GenVec to Release Third Quarter 2011 Financial Results and Conduct a Conference Call on November 9, 2011
8. GenVec to Present at Stifel Nicolaus 2011 Healthcare Conference
9. GenVec Reports Second Quarter 2011 Financial Results
10. GenVec Elects Adel A.F. Mahmoud and Edward M. Connor, Jr. to Board of Directors
11. GenVec to Host First Quarter 2011 Earnings Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Dec. 8, 2016  EIP Pharma, LLC ( ... proof-of-mechanism for neflamapimod (previously code named VX-745), with ... clinical trials that demonstrated significant Alzheimer,s disease relevant ... treatment) and Study 303 (6-week treatment) are the ... Alzheimer,s Disease (CTAD) scientific conference in ...
(Date:12/8/2016)... A Small Business Innovative Research (SBIR) grant ... (NIH) to Phoenix -based NeuroEM Therapeutics, ... grant will seek to determine an optimal set of ... waves to treat Alzheimer,s Disease. The grant will also ... treat other neurologic disorders such as Parkinson,s Disease and ...
(Date:12/8/2016)... New York , December 8, 2016 ... global Diabetes Injection Pens Market is expected to ... compared to US$4.9 bn in 2015. Between the forecast years ... rise at a CAGR of 7.9%. The leading players operating ... A/S, Eli Lilly and Company, AstraZaneca plc., Biocon Ltd., and ...
Breaking Medicine Technology:
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... ... ... CURE Media Group, the nation’s leading digital and print media enterprise focused ... in efforts to combat lung cancer, announced CURE Media Group President Michael J. Hennessy, ... is honored to team up with Upstage Lung Cancer in order to make major ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView ... customers and employees that are both engaging and easy to use. Coming off ... the software company revealed today its plans to roll out new AI-powered self-service ...
(Date:12/8/2016)... ... , ... STAT courier is pleased to announce that due to customer demand, ... expanding their presence in Dallas. One of the most exciting parts for STAT is ... the Dallas and Forth Worth market. STAT takes pride in treating their employees with ...
(Date:12/8/2016)... ... 08, 2016 , ... Vida Health, the digital health platform that ... Canvas Ventures . Other investors include Nokia Growth Partners (NGP) and returning investor ... more consumers who are managing chronic conditions or simply want to improve ...
Breaking Medicine News(10 mins):